Results 111 to 120 of about 148,737 (346)

Progressive systemic sclerosis and autoimmune haemolytic anaemia [PDF]

, 1976
E. Sumithran
openalex   +1 more source

High‐Dose Pulse Glucocorticoid Treatment Prevents White Matter Spinal Cord Pseudoatrophy in Newly Diagnosed Multiple Sclerosis

Annals of Neurology, EarlyView.
Objective Spinal cord (SC) atrophy correlates with and predicts the underlying progressive biology in active and non‐active multiple sclerosis (MS), thereby providing a biomarker for clinical trials and patient management. Initiation of disease‐modifying therapy (DMT) may be followed by early pronounced central nervous system (CNS) volume loss due to ...
Simone Sacco, Nico Papinutto, Vinicius A. Schoeps, Shuiting Cheng, William A. Stern, Haojun Zhao, Antje Bischof, Eduardo Caverzasi, Manula Dombagahawatta, Jeremy Juwono, Amit Akula, Christian Cordano, Alexandra Beaudry‐Richard, Refujia Gomez, Meagan Harms, Adam Santaniello, Riley M. Bove, Jeffrey M. Gelfand, Douglas S. Goodin, Ari J. Green, Jorge R. Oksenberg, Emmanuelle Waubant, Michael R. Wilson, Scott S. Zamvil, Bruce A. C. Cree, Stephen L. Hauser, Roland G. Henry   +26 more
wiley   +1 more source

Long-term evaluation of autologous hematopoietic stem cell transplantation in a patient with progressive systemic sclerosis. [PDF]

Arch Rheumatol, 2021
Kim N, Kim JS, Choi WH, Kim KH, Lee KA, Kim HS.   +5 more
europepmc   +1 more source

The FindMNDBiomarker Program: Protein Changes in Motor Neuron Disease/Amyotrophic Lateral Sclerosis Postmortem Tissue and Biofluids

Annals of Neurology, EarlyView.
Objective Biomarkers of disease pathogenesis are critically needed for amyotrophic lateral sclerosis (ALS) to facilitate diagnosis and patient stratification into appropriate therapeutic trials. Proteomic studies offer significant potential to advance this, but reproducibility across laboratories is a key component toward identifying protein changes ...
Gabrielle L. Adler, Matthew C. Kiernan, Rachel H. Tan   +2 more
wiley   +1 more source

Successful Treatment of Long-Term Severe Progressive Interstitial Pneumonia with Low-Dose Corticosteroid and Azathioprine in a Patient with Diffuse Systemic Sclerosis

Case Reports in Rheumatology, 2012
For progressive interstitial pneumonia (progressive IP) that accompanies diffuse systemic sclerosis (diffuse SSc), no treatment guidelines have yet been established, and it is a complication with a poor prognosis.
Takuya Kotani, Tohru Takeuchi, Shigeki Makino, Toshiaki Hanafusa   +3 more
doaj   +1 more source

Clinical and psychosocioeconomic impact of COVID-19 pandemic on patients of the Indian Progressive Systemic Sclerosis Registry (IPSSR). [PDF]

Rheumatol Adv Pract, 2021
Kavadichanda C, Shobha V, Ghosh P, Wakhlu A, Bairwa D, Mohanan M, Janardana R, Sircar G, Sahoo RR, Joseph S, Negi VS, Khanna D, Shenoy P.   +12 more
europepmc   +1 more source

Effect of Long‐Term Voclosporin Treatment on Renal Histology in Patients With Active Lupus Nephritis With Repeat Renal Biopsies

Arthritis &Rheumatology, EarlyView.
Objective This study characterized the impact of voclosporin on kidney histology in patients with lupus nephritis (LN) who had protocolized repeat kidney biopsies in the AURORA clinical trials. Methods Patients were randomized to voclosporin or placebo treatment for up to 3 years; all patients received mycophenolate mofetil and low‐dose glucocorticoids.
Brad H. Rovin, Clarissa Cassol, Samir V. Parikh, Amit Saxena, Neil Solomons, Vanessa Birardi, Ernie Yap, Clint W. Abner, David R. W. Jayne, Robert B. Huizinga   +9 more
wiley   +1 more source

Clinical and serological comparison of 17 chronic progressive systemic sclerosis (PSS) and 17 CREST syndrome patients matched for sex, age, and disease duration. [PDF]

, 1984
Daniel E. Furst, P. Clements, M. P. Saab, Millie Sterz, Harold E. Paulus   +4 more
openalex   +1 more source

Hand Swelling and Other Non–Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two US Cohorts

Arthritis &Rheumatology, EarlyView.
Objective Raynaud phenomenon (RP) is often the initial clinical manifestation of systemic sclerosis (SSc), but some patients develop other manifestations first. To help elucidate the diversity of SSc presentation in its early stages, we describe the initial clinical manifestations and antinuclear antibody (ANA) profiles of patients in two early SSc ...
Iqtidar Hanif, Shervin Assassi, Maureen D. Mayes, Zsuzsanna H. McMahan, Meng Zhang, Julio Charles, John M. VanBuren, Jessica S. Alvey, Kimia Ghaffari, Elana J. Bernstein, Flavia V. Castelino, Lorinda Chung, Luke Evnin, Tracy M. Frech, Jessica K. Gordon, Faye N. Hant, Laura K. Hummers, Dinesh Khanna, Kimberly S. Lakin, Dorota Lebiedz‐Odrobina, Yiming Luo, Ashima Makol, Jerry A. Molitor, Duncan F. Moore, Carrie Richardson, Nora Sandorfi, Ami A. Shah, Ankoor Shah, Victoria K. Shanmugam, Virginia D. Steen, Elizabeth R. Volkmann, Carleigh Zahn, Brian Skaug   +32 more
wiley   +1 more source

A 3-Year Observational Study of Patients with Progressive Systemic Sclerosis Treated with an Intensified B Lymphocyte Depletion Protocol: Clinical and Immunological Response. [PDF]

J Clin Med, 2021
Rossi D, Sciascia S, Cecchi I, Saracco M, Montabone E, Modena V, Pellerito R, Carignola R, Roccatello D.   +8 more
europepmc   +1 more source